Related Experiment Video
Updated: Aug 5, 2026
09:44
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Quadruplex Bioactive FAND for Treating Acute Liver Failure Induced by Acetaminophen or Hepatectomy
Meng Sun1, Fang Fang1, Juan Liu2
1Key Laboratory of Molecular Medicine and Biotherapy School of Life Sciences Beijing Institute of Technology Beijing P. R. China.
Exploration (Beijing, China)
|August 1, 2026
Summary
A novel nanodrug, FANDHP@FuEVs, composed entirely of active pharmaceutical ingredients, shows promise for treating acute liver failure (ALF). This innovative treatment leverages fusion extracellular vesicles to deliver multiple therapeutic effects, offering a new clinical option.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Regenerative Medicine
Background:
- Acute liver failure (ALF) presents a significant global health challenge with high mortality and limited effective treatments.
- Current therapeutic options for ALF are insufficient, necessitating the development of novel drug delivery systems.
Purpose of the Study:
- To develop a novel nanodrug, FANDHP@FuEVs, based on the full-API nanodrug (FAND) concept for ALF treatment.
- To investigate the therapeutic efficacy and underlying mechanisms of FANDHP@FuEVs in preclinical models of ALF.
Main Methods:
- Construction of FANDHP@FuEVs by hybridizing M2 macrophage-derived EVs (M2-EVs) and mesenchymal stem cell-derived EVs (MSC-EVs), engineered with hepatocyte growth factor (HGF) and polyene phosphatidylcholine (PPC).
- Evaluation of FANDHP@FuEVs targeting efficiency in damaged liver models.
- Assessment of the pleiotropic therapeutic effects (antioxidant, anti-inflammatory, pro-regenerative, macrophage repolarization) of FANDHP@FuEVs in ALF models induced by acetaminophen and hepatectomy.
Main Results:
- FANDHP@FuEVs demonstrated efficient targeting of damaged liver tissue due to the inherent inflammation-tropism of fusion extracellular vesicles (FuEVs).
- The nanodrug exhibited significant therapeutic effects, including antioxidant, anti-inflammatory, pro-regenerative actions, and macrophage repolarization, in ALF models.
- Treatment with FANDHP@FuEVs was effective in ALF models induced by both acetaminophen overdose and hepatectomy, showing clinical relevance.
Conclusions:
- The developed quadruplex bioactive FANDHP@FuEVs offers a versatile and multifaceted therapeutic strategy for ALF.
- Utilizing clinically approved active pharmaceutical ingredients (APIs) to construct full-bioactive nanodrugs presents a promising avenue for clinical translation in ALF treatment.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...